Kiromic BioPharma, Inc. (KRBP) Business Model Canvas

Kiromic BioPharma, Inc. (KRBP): Business Model Canvas [Jan-2025 Updated]

US | Healthcare | Biotechnology | NASDAQ
Kiromic BioPharma, Inc. (KRBP) Business Model Canvas
  • Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • Professional Design: Trusted, Industry-Standard Templates
  • Pre-Built For Quick And Efficient Use
  • No Expertise Is Needed; Easy To Follow

Kiromic BioPharma, Inc. (KRBP) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

In the cutting-edge realm of cancer immunotherapy, Kiromic BioPharma, Inc. (KRBP) emerges as a pioneering force, leveraging its groundbreaking GNET technology to revolutionize personalized cancer treatment. By strategically mapping their innovative business model, this biotech trailblazer is poised to transform oncology research through precision molecular engineering, collaborative partnerships, and breakthrough therapeutic approaches that promise to redefine how we understand and combat cancer at its most fundamental genetic level.


Kiromic BioPharma, Inc. (KRBP) - Business Model: Key Partnerships

Strategic Collaborations with Academic Research Institutions

Institution Research Focus Partnership Details
University of Texas MD Anderson Cancer Center Immunotherapy Research Collaborative research agreement for AI-driven cancer immunotherapy development

Potential Pharmaceutical Development Partnerships

As of 2024, Kiromic BioPharma has been exploring strategic pharmaceutical development partnerships to advance its immunotherapy platform.

  • Potential collaboration with pharmaceutical companies specializing in oncology research
  • Discussions with biotechnology firms for joint drug development initiatives

Immunotherapy Research Network Alliances

Network Collaboration Type Research Focus
Cancer Immunotherapy Network Research Alliance Advanced immunological targeting strategies

Biotechnology Platform Technology Partners

Kiromic BioPharma has been developing partnerships to enhance its AI-driven biotechnology platforms.

  • AI technology integration partnerships
  • Computational biology collaboration agreements

Total partnership-related research and development expenditure for 2023: $2.1 million

Number of active research collaborations as of Q4 2023: 3 strategic partnerships


Kiromic BioPharma, Inc. (KRBP) - Business Model: Key Activities

Developing Personalized Immunotherapies

As of Q4 2023, Kiromic BioPharma focused on developing personalized immunotherapies targeting specific cancer types.

Research Focus Current Status Investment
KRBP-T0 Personalized Immunotherapy Preclinical Stage $3.2 million allocated
Gene Editing Platforms Active Development $2.7 million invested

Cancer Treatment Research and Development

Kiromic BioPharma's R&D efforts concentrated on advanced cancer treatment strategies.

  • Total R&D expenditure in 2023: $5.9 million
  • Research focus areas: Lung cancer, brain cancer, and solid tumors
  • Number of ongoing research projects: 4

Molecular Engineering and Gene Editing

The company utilized advanced molecular engineering techniques for therapeutic development.

Technology Development Stage Patent Status
CRISPR Gene Editing Platform Advanced Research 2 Provisional Patents Filed
Precision Immunotherapy Techniques Preclinical Validation 1 Patent Pending

Clinical Trial Management and Execution

Clinical trial activities were critical to Kiromic BioPharma's research strategy.

  • Active clinical trials in 2023: 2
  • Total clinical trial budget: $4.5 million
  • Institutional research collaborations: 3 academic medical centers

Biotech Product Innovation

Continuous innovation remained a core strategy for the company's product development.

Innovation Area Investment Expected Outcome
Immunotherapy Platform $3.6 million Advanced Therapeutic Prototype
Gene Editing Technologies $2.9 million Novel Treatment Approaches

Kiromic BioPharma, Inc. (KRBP) - Business Model: Key Resources

Proprietary GNET Immunotherapy Technology Platform

Kiromic BioPharma's core technology platform, GNET, represents a critical key resource for the company's immunotherapy development.

Technology Aspect Specific Details
Platform Type Genomic Network Engineering Technology (GNET)
Patent Status Multiple pending and granted patents
Development Stage Advanced preclinical research phase

Specialized Scientific Research Team

The company's research team comprises specialized professionals in genomics and immunotherapy.

Team Composition Number
Total Research Personnel Approximately 22 employees
PhD Level Researchers 12 researchers

Advanced Molecular Biology Laboratory Facilities

  • Located in Houston, Texas
  • Equipped with state-of-the-art genomic sequencing instruments
  • Biosafety Level 2 (BSL-2) certified laboratory

Intellectual Property Portfolio

IP Category Count
Total Patent Applications 7 patent applications
Granted Patents 3 patents

Genomic and Computational Research Capabilities

Kiromic BioPharma maintains sophisticated computational infrastructure for genomic research.

  • High-performance computing systems
  • Advanced bioinformatics software
  • Machine learning algorithms for genomic analysis

Kiromic BioPharma, Inc. (KRBP) - Business Model: Value Propositions

Precision Targeted Cancer Immunotherapies

Kiromic BioPharma focuses on developing precision targeted cancer immunotherapies utilizing CRISPR gene editing technology.

Therapy Type Target Cancer Development Stage
CRISPR-Enhanced CAR-T Lung Cancer Preclinical
Gene-Modified Immunotherapy Ovarian Cancer Research Phase

Personalized Treatment Approaches

Kiromic develops personalized immunotherapies with patient-specific genetic modifications.

  • Genetic profiling for individualized treatment
  • Patient-specific CAR-T cell engineering
  • Precision targeting of cancer cell mutations

Innovative Gene Editing Solutions

Advanced CRISPR gene editing platform targeting complex genetic modifications.

Technology Modification Capability Precision Level
CRISPR-Cas9 Multiple Gene Editing High Precision

Potential Breakthrough in Oncology Treatment

Kiromic's approach aims to address limitations in current cancer immunotherapies.

Advanced Therapeutic Targeting Mechanisms

Developing sophisticated targeting strategies for enhanced cancer cell elimination.

Targeting Strategy Mechanism Potential Efficacy
Multi-Antigen Targeting Genetic Modification Reduced Tumor Resistance

Kiromic BioPharma, Inc. (KRBP) - Business Model: Customer Relationships

Direct Engagement with Medical Research Institutions

As of Q4 2023, Kiromic BioPharma maintains direct research collaborations with 7 academic medical centers focused on immuno-oncology research.

Institution Type Number of Active Collaborations Research Focus
Academic Medical Centers 7 Immuno-oncology
Research Universities 3 Precision Medicine

Collaborative Scientific Partnerships

Kiromic has established strategic partnerships targeting AI-driven drug discovery platforms.

  • Total active scientific partnerships: 5
  • Computational biology collaboration agreements: 3
  • AI-driven research platforms: 2

Professional Medical Community Interactions

Kiromic BioPharma participates in 12 annual oncology conferences and medical symposia as of 2024.

Conference Type Annual Participation Engagement Method
Oncology Conferences 8 Poster Presentations
Medical Symposia 4 Scientific Panel Discussions

Clinical Trial Participant Communication

As of January 2024, Kiromic manages ongoing clinical trials with 127 active participants across multiple studies.

  • Active clinical trial participants: 127
  • Communication channels: Electronic patient portals, direct clinical coordinator contact
  • Patient follow-up frequency: Quarterly assessments

Transparent Research Development Updates

Kiromic provides quarterly investor and research updates through multiple communication channels.

Update Channel Frequency Information Type
Investor Presentations Quarterly Financial and Research Progress
Scientific Publications Bi-annually Research Findings
Corporate Website Updates Monthly Research Milestones

Kiromic BioPharma, Inc. (KRBP) - Business Model: Channels

Scientific Conference Presentations

As of Q4 2023, Kiromic BioPharma participated in 3 major oncology and immunotherapy conferences, including the American Association for Cancer Research (AACR) Annual Meeting.

Conference Presentation Type Date
AACR Annual Meeting Poster Presentation April 2023
Society for Immunotherapy of Cancer (SITC) Research Platform November 2023

Peer-Reviewed Medical Journal Publications

In 2023, Kiromic published 2 peer-reviewed articles in scientific journals.

  • Published in Cancer Immunology Research
  • Published in Journal of Immunotherapy

Direct Pharmaceutical Industry Outreach

Kiromic engaged with 7 potential pharmaceutical partners in 2023 for potential collaboration and licensing opportunities.

Pharmaceutical Company Interaction Type Potential Focus
Large Pharma Company A Initial Discussion AI-driven Immunotherapy
Oncology Specialty Firm B Licensing Exploration KRBP Proprietary Platform

Digital Scientific Communication Platforms

Kiromic maintains active digital presence across 3 primary scientific communication platforms.

  • LinkedIn Scientific Network
  • ResearchGate Professional Network
  • Company Website Scientific Section

Investor and Stakeholder Communications

In 2023, Kiromic conducted 4 investor relations events and conference calls.

Event Type Frequency Participant Count
Quarterly Earnings Call 4 times Approximately 50-75 participants
Investor Presentation 2 times 100-150 attendees

Kiromic BioPharma, Inc. (KRBP) - Business Model: Customer Segments

Oncology Research Institutions

As of Q4 2023, Kiromic BioPharma targets 127 specialized oncology research institutions in North America.

Institution Type Number of Potential Customers Annual Research Budget
NCI-Designated Cancer Centers 71 $3.2 billion
Academic Medical Centers 56 $2.7 billion

Pharmaceutical Companies

Kiromic targets 42 pharmaceutical companies with immuno-oncology research programs.

  • Top 20 global pharmaceutical companies with oncology focus
  • Biotechnology firms specializing in immunotherapy
  • Mid-sized pharmaceutical research organizations

Cancer Treatment Centers

Center Classification Total Centers Potential Market Penetration
Comprehensive Cancer Centers 51 38%
Community Cancer Centers 1,500 12%

Academic Research Laboratories

Market coverage includes 238 academic research laboratories focused on immunogenomics.

  • Research universities with dedicated oncology programs
  • Genomic research centers
  • Translational medicine laboratories

Biotechnology Investors

Investor Category Number of Potential Investors Estimated Investment Capacity
Venture Capital Firms 87 $1.6 billion
Private Equity Investors 53 $2.3 billion

Kiromic BioPharma, Inc. (KRBP) - Business Model: Cost Structure

Research and Development Expenses

For the fiscal year ended December 31, 2022, Kiromic BioPharma reported R&D expenses of $8.7 million.

Fiscal Year R&D Expenses
2022 $8.7 million
2021 $7.3 million

Clinical Trial Investments

The company's clinical trial investments for 2022 totaled approximately $5.2 million, focusing on immuno-oncology programs.

Personnel and Scientific Talent Acquisition

Personnel Category Annual Cost
Scientific Staff $3.5 million
Administrative Personnel $1.8 million

Laboratory Equipment and Technology Maintenance

Total equipment and technology maintenance costs for 2022 were $2.1 million.

  • Specialized biotech equipment: $1.3 million
  • Technology infrastructure: $0.8 million

Intellectual Property Protection Costs

Annual intellectual property protection expenses were $650,000 in 2022.

IP Protection Category Annual Cost
Patent Filing $450,000
Legal Consultation $200,000

Total Operational Cost Structure for 2022: $20.25 million


Kiromic BioPharma, Inc. (KRBP) - Business Model: Revenue Streams

Potential Licensing of Immunotherapy Technologies

As of Q4 2023, Kiromic BioPharma has not reported any active licensing revenue from its immunotherapy technologies.

Research Grant Funding

Year Grant Source Amount
2022 NIH Small Business Innovation Research (SBIR) $299,980
2023 Total Research Grant Funding $336,000

Future Therapeutic Product Commercialization

No commercial revenue reported as of 2024. Pipeline products are still in pre-clinical and clinical development stages.

Strategic Partnership Agreements

  • No active strategic partnership agreements generating revenue as of 2024
  • Ongoing research collaborations without immediate financial returns

Potential Milestone Payments from Pharmaceutical Collaborations

Collaboration Status Potential Milestone Payment Range
Potential Future Collaborations $0 - $500,000 estimated

Total Company Revenue for 2023: $336,000


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.